期刊文献+

硫酸氢氯吡格雷片处方和制备工艺研究 被引量:4

Investigation of Formulation and in-Process Parameters of Clopidogrel Bisulfate Tablets
原文传递
导出
摘要 目的制备稳定的硫酸氢氯吡格雷片(CPG,Ⅰ型),并考察影响颗粒特性的关键处方和工艺参数,以解决压片时的黏片现象,并确保稳定性。方法研究原料辅料的相容性并筛选处方,考察直接压片、滚压法和熔融法对杂质、压片特性和溶出度的影响。结果影响CPG稳定性最显著的因素是水分,其次为光照和温度;与滚压法、直接压片相比,熔融制粒的工艺更优;硬脂富马酸钠可防止压片时的黏片现象;溶出度与进口"波立维"相似因子f2>50;3个月加速实验结果表明,稳定性良好。结论制备工艺重现性良好,片剂质量稳定。 OBJECTIVE To investigate the formulation and process for preparing stable clopidogrel bisulfate tablets(Form I) by elucidating the critical formulation and in-process parameters affecting critical granule properties,in order to solve sticking problems in tablet processing as well as improving stability under storage.METHODS Drug-excipient interactions were evaluated,and different dry granulations such as direct compression,melt granulation and roller compaction were compared,in terms of impurity levels,tablet properties and in vitro dissolution.RESULTS The stability of free clopidogrel bisulfate was liable to the high moisture,strong light and elevated temperature.Compared with direct compression and roller compaction,melt granulation was more suitable to prepare clopidogrel bisulfate tablet.Sodium stearyl fumarate avoided sticking problem in tablet processing with PEG 6000.Comparable dissolution profiles were obtained and similar to that of Pavix of Sinofi,with the similar factors above 50.Furthermore,the accelerated stability test suggested that tablets prepared by melt granulation under storage at 40 C and 75% RH for 3 months were stable and showed good physicochemical properties.CONCLUSION The CPG tablets were stable and the established processes were simple and reproducible.
出处 《中国药学杂志》 CAS CSCD 北大核心 2011年第2期117-123,共7页 Chinese Pharmaceutical Journal
关键词 硫酸氢氯吡格雷 熔融制粒 PEG6000 相容性 稳定性 体外溶出 clopidogrel bisulfate melt granulation PEG 6000 compatibility stability in vitro dissolution
  • 相关文献

参考文献8

  • 1倪唤春,范维琥.抗血小板新药——氯吡格雷[J].中国新药杂志,2001,10(12):888-891. 被引量:44
  • 2BOUSQUET A, CASTTO B, SAINT-GERMAIN J. Polymorphic clopidogrel hydrogenesulphate form. US, 6429210. [ P].2002- 08-26.
  • 3MOHAN A, HARIHARAN M, VIKRAMAN E, et al. Identification and characterization of a principal oxidation impurity in clopi- dogrel drug substance and drug product [ J ]. J Pharm Biomed Anal, 2008,47( 1 ) :183-189.
  • 4GOMEZ Y, ADAMS E, HOOGMARTENTS J. (2004) Analysis of purity in 19 drug product tablets containing clopidogrel: 18 copies versus the original brand [ J ]. J Pharm Biomed Anal, 2004,34 (2) : 341-348.
  • 5USP. 30 NF25[S]. 2006:1803-1804.
  • 6HEGDE D A, CHOTHE S S, CHONGARI I S, et al. Novel stable pharmaceutical compositions of clopidogrel bisulfate and process of preparation thereof. WO, 2008122994[P].2008-10-16.
  • 7SHERMAN B C. Clopidugrel bisulfate tablet formulation. US, 6914141 [ P]. 2005-01-05.
  • 8GAOY WANGHG ZHANGRH etal.Melt granulation in high shear mixer-research progress .中国药学杂志,1999,34(3):149-152.

二级参考文献3

共引文献43

同被引文献31

引证文献4

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部